Drug Search Results
More Filters [+]

Azilsartan medoxomil

Alternative Names: azilsartan medoxomil
Latest Update: 2024-04-01
Latest Update Note: Clinical Trial Update

Product Description

Azilsartan medoxomil (Edarbi, Takeda) is a new addition to the ARB class of antihypertensive agents. As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278144/)

Mechanisms of Action: ARB Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Canada | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Mexico | Netherlands | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azilsartan medoxomil

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events